JP2019504895A - スギ花粉エピトープを封入するｔｉｍｐ（組織性メタロプロテアーゼ阻害因子） - Google Patents

スギ花粉エピトープを封入するｔｉｍｐ（組織性メタロプロテアーゼ阻害因子） Download PDF

Info

Publication number
JP2019504895A
JP2019504895A JP2018560744A JP2018560744A JP2019504895A JP 2019504895 A JP2019504895 A JP 2019504895A JP 2018560744 A JP2018560744 A JP 2018560744A JP 2018560744 A JP2018560744 A JP 2018560744A JP 2019504895 A JP2019504895 A JP 2019504895A
Authority
JP
Japan
Prior art keywords
composition
particles
antigen
cathepsin
cedar pollen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018560744A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019504895A5 (enExample
Inventor
アール． ゲッツ，ダニエル
アール． ゲッツ，ダニエル
Original Assignee
クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド
クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド, クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド filed Critical クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド
Publication of JP2019504895A publication Critical patent/JP2019504895A/ja
Publication of JP2019504895A5 publication Critical patent/JP2019504895A5/ja
Priority to JP2022059997A priority Critical patent/JP2022101576A/ja
Priority to JP2025001876A priority patent/JP2025069142A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2018560744A 2016-02-09 2017-02-09 スギ花粉エピトープを封入するｔｉｍｐ（組織性メタロプロテアーゼ阻害因子） Pending JP2019504895A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022059997A JP2022101576A (ja) 2016-02-09 2022-03-31 スギ花粉エピトープを封入するｔｉｍｐ（組織性メタロプロテアーゼ阻害因子）
JP2025001876A JP2025069142A (ja) 2016-02-09 2025-01-06 スギ花粉エピトープを封入するｔｉｍｐ（組織性メタロプロテアーゼ阻害因子）

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662293261P 2016-02-09 2016-02-09
US62/293,261 2016-02-09
PCT/US2017/017248 WO2017139498A1 (en) 2016-02-09 2017-02-09 Timps encapsulating japanese cedar pollen epitopes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022059997A Division JP2022101576A (ja) 2016-02-09 2022-03-31 スギ花粉エピトープを封入するｔｉｍｐ（組織性メタロプロテアーゼ阻害因子）

Publications (2)

Publication Number Publication Date
JP2019504895A true JP2019504895A (ja) 2019-02-21
JP2019504895A5 JP2019504895A5 (enExample) 2020-03-19

Family

ID=59563413

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018560744A Pending JP2019504895A (ja) 2016-02-09 2017-02-09 スギ花粉エピトープを封入するｔｉｍｐ（組織性メタロプロテアーゼ阻害因子）
JP2022059997A Pending JP2022101576A (ja) 2016-02-09 2022-03-31 スギ花粉エピトープを封入するｔｉｍｐ（組織性メタロプロテアーゼ阻害因子）
JP2025001876A Pending JP2025069142A (ja) 2016-02-09 2025-01-06 スギ花粉エピトープを封入するｔｉｍｐ（組織性メタロプロテアーゼ阻害因子）

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022059997A Pending JP2022101576A (ja) 2016-02-09 2022-03-31 スギ花粉エピトープを封入するｔｉｍｐ（組織性メタロプロテアーゼ阻害因子）
JP2025001876A Pending JP2025069142A (ja) 2016-02-09 2025-01-06 スギ花粉エピトープを封入するｔｉｍｐ（組織性メタロプロテアーゼ阻害因子）

Country Status (3)

Country Link
JP (3) JP2019504895A (enExample)
KR (1) KR20180105243A (enExample)
WO (1) WO2017139498A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021050146A (ja) * 2019-09-24 2021-04-01 鳥居薬品株式会社 ヒノキ花粉抗原に対するモノクローナル抗体及びその用途
JP2024518277A (ja) * 2021-04-16 2024-05-01 クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド 免疫寛容の維持を追跡する方法

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011289579B2 (en) 2010-08-10 2016-11-17 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
WO2013163176A1 (en) 2012-04-23 2013-10-31 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
CA2907915C (en) 2013-04-03 2023-03-07 Allertein Therapeutics, Llc Immunomodulatory nanoparticle compositions comprising a plurality of nanoparticles comprising biodegradable or biocompatible polymers and hydrophilic and hydrophobic cellular components
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
CA2946064C (en) 2014-02-21 2023-09-26 Ecole Polytechnique Federale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US20190365656A1 (en) * 2016-01-04 2019-12-05 Cour Pharmaceuticals Development Company, Inc. Particles encapsulating fusion proteins containing linked epitopes
EP3638296A1 (en) 2017-06-16 2020-04-22 The University Of Chicago Compositions and methods for inducing immune tolerance
EP3790577A4 (en) 2018-05-09 2022-04-27 The University of Chicago COMPOSITIONS AND METHODS RELATED TO IMMUNTOLERANCE
US12528848B2 (en) 2018-05-25 2026-01-20 The Wistar Institute Of Anatomy And Biology Tumor-specific neoantigens and methods of using the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007024026A1 (ja) * 2005-08-25 2007-03-01 Taiho Pharmaceutical Co., Ltd. Ｔ細胞認識エピトープペプチドを固定化又は内包化した生分解性ナノ粒子
WO2015023796A2 (en) * 2013-08-13 2015-02-19 Shea Lonnie D Peptide conjugated particles

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014524902A (ja) * 2011-06-14 2014-09-25 アメリカ合衆国 Ｔｅｍ８抗体、そのコンジュゲートおよびそれらの使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007024026A1 (ja) * 2005-08-25 2007-03-01 Taiho Pharmaceutical Co., Ltd. Ｔ細胞認識エピトープペプチドを固定化又は内包化した生分解性ナノ粒子
WO2015023796A2 (en) * 2013-08-13 2015-02-19 Shea Lonnie D Peptide conjugated particles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EUROPEAN JOURNAL OF IMMUNOLOGY, 19 AUG 2016, VOL.46, ISSUE S1, ABSTRACT NO. 2138, JPN6021003925, ISSN: 0004440080 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021050146A (ja) * 2019-09-24 2021-04-01 鳥居薬品株式会社 ヒノキ花粉抗原に対するモノクローナル抗体及びその用途
JP2024518277A (ja) * 2021-04-16 2024-05-01 クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド 免疫寛容の維持を追跡する方法

Also Published As

Publication number Publication date
KR20180105243A (ko) 2018-09-27
JP2022101576A (ja) 2022-07-06
JP2025069142A (ja) 2025-04-30
WO2017139498A1 (en) 2017-08-17

Similar Documents

Publication Publication Date Title
JP2025069142A (ja) スギ花粉エピトープを封入するｔｉｍｐ（組織性メタロプロテアーゼ阻害因子）
JP7586863B2 (ja) 共有ポリマー抗原コンジュゲート化粒子
US11389517B2 (en) Peptide conjugated particles
JP7491869B2 (ja) ペプチドコンジュゲート粒子
CA2918823C (en) Peptide conjugated particles
HK40058733A (zh) 肽缀合颗粒

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210430

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210803

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220331

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220331

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220511

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220530

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220531

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220701

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220705

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240513